Skip to main content
Clinical Trials/JPRN-UMIN000004410
JPRN-UMIN000004410
Completed
Phase 3

Randomized phase III study of adjuvant chemotherapy with combination therapy of gemcitabine and S-1 vs. gemcitabine alone in patients with resected pancreatic cancer (JSAP-04) - Phase III study of gemcitabine and S-1 combination therapy for resected pancreatic cancer

Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)0 sites300 target enrollmentOctober 20, 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Resected pancreatic cancer
Sponsor
Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)
Enrollment
300
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 20, 2010
End Date
November 1, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) History of serious complications related to surgery 2\) Patients under treatment with phenytoin, warfarin potassium or flucytosine. 3\) Uncontrolled watery diarrhea 4\) Sever mental disorder 5\) Active infection 6\) Serious complications 7\) Pulmonary fibrosis or interstitial pneumonia 8\) Clinically significant pleural effusions or ascites 9\) Active double cancer (synchronous double cancer or asynchronous double cancer with disease\-free duration of 2 years or less) 10\) History of chemotherapy or radiotherapy for other malignant disease within one year 11\) Unable to receive contrast enhanced CT nor MRI due to allergic reaction to contrast medium 12\) Pregnant females, possibly pregnant females, females wishing to become pregnant, and males that are currently attempting to produce a pregnancy 13\) Inadequate physical condition, as diagnosed by primary physician

Outcomes

Primary Outcomes

Not specified

Similar Trials